Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Randomized, Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma

NCT03029780 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT03029780
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03029780 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Randomized, Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 2
Overall status
Completed
Start date
February 16, 2017
Completion date
June 15, 2021
Enrollment
104 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma